• Novo Nordisk pays $70M for a Phase 1-ready cardiometabolic disorder drug

    2 monthes ago - By MedCity News

    Novo Nordisk is acquiring global rights to a Ventus Therapeutics drug candidate with potential applications in cardiometabolic disorders such as NASH and chronic kidney disease. The small molecule blocks a protein that has become an attractive target for big pharmaceutical companies, such as Roche and Novartis.
    Read more ...